Health News

EPALINGES, Switzerland--(BUSINESS WIRE)--Novigenix AI, a leader in AI-driven healthcare solutions, today announced the presentation of new data at the American Association for Cancer Research (AACR) 2026 Annual Meeting demonstrating, for the first time in a human clinical setting, the dynamic role of the immune system in response to radioligand therapy in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET).1 The study, conducted in collaboration with RadioMedix, Inc....

HERNDON, Va.--(BUSINESS WIRE)--Sophia Learning announces a partnership with NurseDash....

MADISON, Wis.--(BUSINESS WIRE)--Promega will distribute NimaGen's IDseek® MPS library prep kits for forensic casework through a new distribution agreement with NimaGen....

NEWTON, Mass.--(BUSINESS WIRE)--4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program...

LEXINGTON, Mass.--(BUSINESS WIRE)--Valo Health, Inc. (“Valo”), a pioneer in the use of human data and AI to accelerate drug discovery and development, today announced the appointment of Chris Anagnostopoulos, PhD, C.Stat, to the newly created position of Chief Causal AI Officer. In this role, Dr. Anagnostopoulos will lead the advancement of Valo’s human causal biology platform, translating large-scale, real‑world human data into causal insights that inform drug discovery. Valo aims to improve c...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of a 56-week post hoc analysis of the effects of LYBALVI® (olanzapine and samidorphan) on negative symptoms in adults living with schizophrenia in the peer-reviewed publication The Journal of Clinical Psychiatry. The analysis—titled “The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia”—found that treatment with LYBALVI was associat...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its HeliconTM peptide platform to drug historically undruggable targets, today announced the appointment of Helen Ho, Ph.D., as the company’s Chief Business and Strategy Officer, and the promotion of Thomas Kotarakos to Chief Financial Officer. Dr. Ho brings extensive experience scaling biopharmaceutical companies, l...

SAN FRANCISCO--(BUSINESS WIRE)--Freed, the AI clinician assistant trusted by more than 26,000 clinicians and institutions across 100+ specialties, today announced the launch of Freed Front Desk, an AI-powered receptionist that answers clinic calls around the clock, captures every patient request, and routes structured summaries to staff through a shared inbox, with a 90% reduction in hold times, no voicemails, and no IT setup required. When Freed launched its AI scribe in 2023, it gave clinicia...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based organizations to apply for a grant to create training content for healthcare providers to deliver investigational COMP360 psilocybin treatment, if approved. Many high-quality training organizations already exist and have trained thousands of HCPs in core and psilocybin...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on M...